| 7.45 -0.22 (-2.87%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.81  |
1-year : | 10.53 |
| Resists | First : | 8.4 |
Second : | 9.02 |
| Pivot price | 8.38 |
|||
| Supports | First : | 7.4 |
Second : | 6.15 |
| MAs | MA(5) : | 7.96 |
MA(20) : | 8.45 |
| MA(100) : | 7.44 |
MA(250) : | 7.3 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 13.8 |
| RSI | RSI(14): 29.8 |
|||
| 52-week | High : | 10.07 | Low : | 5.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XERS ] has closed below the lower bollinger band by 8.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 49.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.94 - 8.02 | 8.02 - 8.06 |
| Low: | 7.24 - 7.34 | 7.34 - 7.4 |
| Close: | 7.34 - 7.5 | 7.5 - 7.59 |
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Wed, 09 Sep 2026
Xeris Biopharma Holdings, Inc. at XP-8121 Program Overview Transcript - GuruFocus
Wed, 09 Sep 2026
XERS: XP-8121 enters Phase 3 in 2026, targeting $1–3B peak revenue and 2030 FDA approval - TradingView
Wed, 09 Sep 2026
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS) - stocktitan.net
Wed, 09 Sep 2026
An estimated 3 to 5 million lack thyroid control. Xeris is developing a weekly injection. - stocktitan.net
Wed, 26 Aug 2026
Xeris Announces Details for XP-8121 Program Overview Webinar - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 182 (M) |
| Shares Float | 176 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 60 (%) |
| Shares Short | 8,730 (K) |
| Shares Short P.Month | 10,080 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | -5.2 % |
| Operating Margin | 5.6 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 28.7 % |
| Gross Profit (p.s.) | 1.59 |
| Sales Per Share | 1.83 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 57 (M) |
| Levered Free Cash Flow | 52 (M) |
| PE Ratio | -74.5 |
| PEG Ratio | 0 |
| Price to Book value | -124.17 |
| Price to Sales | 4.04 |
| Price to Cash Flow | 23.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|